BioInvent International
27.50 SEK
+7.21 %
BINV
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
BioInvent International is a biotechnology company focused on the development of antibody therapies for cancer treatment. The company researches new treatments that can improve patient outcomes and quality of life. The company operates globally with a presence in international markets. BioInvent International was founded in 1983 and is headquartered in Lund.
Read moreRevenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
Interim report Q2'26
Interim report Q3'26
BioInvent to Host Virtual KOL Event to Discuss BI-1808 for the Treatment of Ovarian Cancer, on May 27, 2026
BioInvent’s TNFR2 Antibody BI-1808 Shows Strong Activity and Immune Activation as Single Agent and in Combination with KEYTRUDA® (pembrolizumab) in Advanced CTCL (EHA 2026)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
